Abbott settles DOJ infant formula case, no admission of fault

What happened

Abbott Laboratories announced an agreement with the U.S. Department of Justice to resolve claims related to the 2022 infant formula recall at its Sturgis, Michigan facility. The settlement does not represent any finding of fault or liability, and the government indicated that its criminal investigation on the matter is closed. Tests by regulators of unopened products from the homes of the infants under investigation were negative for Cronobacter sakazakii, and no unopened distributed Abbott infant formulas have ever tested positive for the pathogen. This resolution removes a long-standing legal overhang from Abbott's nutrition business, which has since faced separate challenges including volume declines and pricing actions. While the settlement provides clarity on the recall, it does not address Abbott's broader near-term concerns such as FDA scrutiny at its diabetes care facility or integration of the Exact Sciences acquisition.

Implication

The agreement eliminates a potential source of reputational and financial risk tied to the 2022 infant formula recall, but the financial terms were not disclosed and the resolution itself adds no revenue or earnings benefit. Abbott still faces declining nutrition volumes, an FDA warning letter at its Alameda Libre manufacturing site, and ongoing EPS dilution from the Exact Sciences acquisition. The stock trades at a premium valuation of 34.5x earnings, leaving little room for disappointment in device growth or diabetes quality remediation. Investors should view the settlement as a modest positive that reduces tail risk, not as a catalyst for re-rating the shares. The investment thesis remains unchanged: wait for a more attractive entry near $98 where execution upside is better compensated.

Thesis delta

The thesis remains WAIT as the settlement resolves a specific legacy issue but does not address the core drivers of Abbott's near-term valuation: weak nutrition, FDA scrutiny on Libre, and Exact Sciences dilution. The elimination of this legal overhang modestly reduces downside risk but does not justify upgrading the stock at its current price. No change to rating or price targets is warranted.